Stictic acid
Based on 1 Customer Validation
Stictic acid is a Depsidone. Stictic acid is found in the edible lichens Lobaria pindarensis and Lobaria pulmonaria. Stictic acid inhibits LPS/Aβ42-induced mRNA expression of iNOS, IL-1β, TNF-α, and IL-6, and decreases LPS-induced COX-2 protein expression. Stictic acid inhibits Aβ42 fibril formation and aggregation. Stictic acid scavenges superoxide anions. Stictic acid exhibits anticancer activity against colon adenocarcinoma. Stictic acid is used in research on Alzheimer's disease and colon adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.5%
- CAS No.: 549-06-4
- Formule: C19H14O9
- Masse moléculaire:386.31
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
IC50 & Target
[1]|
iNOS |
IL-1β |
IL-6 |
COX-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
29.29 μg/mL
|
Growth inhibition of human colon adenocarcinoma HT-29 cells assessed by MTT assay after 48 hrs incubation.
Growth inhibition of human colon adenocarcinoma HT-29 cells assessed by MTT assay after 48 hrs incubation.
|
stictic-acid-inhibits-cell-growth-of-human-colon-adenocarcinoma-ht-29-cells |
| MRC5 | IC50 |
2478.40 μg/mL
|
Growth inhibition of human fetal lung fibroblast MRC-5 cells assessed by MTT assay after 48 hrs incubation.
Growth inhibition of human fetal lung fibroblast MRC-5 cells assessed by MTT assay after 48 hrs incubation.
|
stictic-acid-inhibits-cell-growth-of-human-colon-adenocarcinoma-ht-29-cells |
In Vitro
Stictic acid (30 μM; pretreatment for 3 h before LPS stimulation) completely inhibits LPS-induced mRNA expression of IL-6, IL-1β, iNOS, and TNF-α in RAW264.7 cells[1].
Stictic acid (30 μM; pretreatment for 3 h before LPS stimulation) inhibits LPS-induced mRNA expression of IL-6, IL-1β, iNOS, and TNF-α in BV2 cells[1].
Stictic acid (30 μM; pretreated for 3 h before LPS stimulation) significantly reduces COX-2 protein expression in LPS-induced RAW264.7 cells[1].
Stictic acid (30 μM; pretreatment for 3 h before LPS stimulation) inhibits LPS-induced COX-2 protein expression in BV2 cells[1].
Stictic acid (30 μM; pretreatment for 3 h before LPS stimulation) inhibits LPS-induced phagocytosis in BV2 cells[1].
Stictic acid (30 μM; pretreatment for 3 h before Aβ42 stimulation) inhibits Aβ42-induced mRNA expression of IL-6, IL-1β, iNOS, and TNF-α in BV2 cells[1].
Stictic acid (3000 μM) exhibits weak DPPH radical scavenging activity of approximately 10% at 3000 μM[2].
Stictic acid (0.01-100 μM; 48 h) inhibits the growth of HT-29 colon adenocarcinoma cells with an IC50 of 29.29 µg/mL, while showing lower growth inhibition against non-malignant MRC-5 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:30 μM
-
Incubation Time:3 h (pre-treatment before LPS challenge); 12 h (post-LPS challenge)
-
Result:Showed a full suppression on the LPS-induced mRNA expressions of IL-6, IL-1β, iNOS and TNF-α, similar to that of dexamethasone.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:30 μM
-
Incubation Time:3 h (pre-treatment before LPS challenge); 12 h (post-LPS challenge)
-
Result:Markedly reduced the expression of COX-2, as induced by LPS.
-
Cell Line:BV2 microglial cells
-
Concentration:30 μM
-
Incubation Time:3 h (pre-treatment before LPS challenge); 12 h (post-LPS challenge)
-
Result:Showed robust suppression on the LPS-induced mRNA expressions of IL-6, IL-1β, iNOS and TNF-α.
-
Cell Line:BV2 microglial cells
-
Concentration:30 μM
-
Incubation Time:3 h (pre-treatment before LPS challenge); 12 h (post-LPS challenge)
-
Result:Showed robust suppression on the LPS-induced protein expression of COX-2.
-
Cell Line:BV2 microglial cells
-
Concentration:30 μM
-
Incubation Time:3 h (pre-treatment before Aβ42 challenge); 12 h (post-Aβ42 challenge)
-
Result:Showed suppression on the Aβ42-induced mRNA expressions of IL-6, IL-1β, iNOS and TNF-α.
-
Cell Line:HT-29, MCF-7, MRC-5
-
Concentration:10-8 M to 10-4 M
-
Incubation Time:48 h
-
Result:Inhibited HT-29 cell growth with an IC50 of 29.29 µg/mL.
Inhibited MRC-5 cell growth with an IC50 of 2478.40 µg/mL.
Was 689-fold more sensitive to HT-29 cells compared to MCF-7 cells.
Chemical Information
-
CAS No. 549-06-4
-
Appearance Solid
-
Masse moléculaire 386.31
-
Formule C19H14O9
-
Color White to off-white
-
SMILES
O=CC1=C(OC(C2=C(C(OC2O)=O)C(O)=C3C)=C3OC4=O)C4=C(C)C=C1OC
-
Structure Classification
-
Initial Source
Lobaria pulmonaria
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 11 mg/mL (28.47 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5886 mL | 12.9430 mL | 25.8859 mL | 64.7149 mL |
| 5 mM | 0.5177 mL | 2.5886 mL | 5.1772 mL | 12.9430 mL | |
| 10 mM | 0.2589 mL | 1.2943 mL | 2.5886 mL | 6.4715 mL | |
| 15 mM | 0.1726 mL | 0.8629 mL | 1.7257 mL | 4.3143 mL | |
| 20 mM | 0.1294 mL | 0.6471 mL | 1.2943 mL | 3.2357 mL | |
| 25 mM | 0.1035 mL | 0.5177 mL | 1.0354 mL | 2.5886 mL |
Stictic acid Related Classifications
HY-126779 Related Classifications
Powered by Bioz